Skip to main content
Fig. 3 | Arthritis Research & Therapy

Fig. 3

From: Application of systems biology-based in silico tools to optimize treatment strategy identification in Still’s disease

Fig. 3

Systems biology-based MoA models of canakinumab and tocilizumab focused on innate immune system modulation. Canakinumab preferably modulates NF-κB, IL-8 (CXCL8), MyD88, S100A9, and ATG5, which are involved in processes of general innate immune inflammation, neutrophil recruitment, activation, and autophagy, whereas tocilizumab preferably modulates FCGR1, which is involved in neutrophil activation

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us